Chimerix, Inc., a Durham, NC-based pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, completed a $45m Series F financing.
The round was led by New Leaf Venture Partners, with participation from new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.
In connection with the funding, James Niedel, M.D., Ph.D.,Managing Director of New Leaf Venture Partners, and Arthur M. Pappas, Managing Partner of Pappas Ventures, will join Chimerix’s board of directors.
Graham Crooke, M.D., of Helix Ventures will retire from the board.
The company intends to use the proceeds from this financing to support the development of its two clinical-stage candidates, CMX001 and CMX157.
CMX001 is in clinical development as a broad spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients, and has a potential dual use as a medical countermeasure in the event of a smallpox release.
CMX157 is a nucleoside analogue in development for the treatment of HIV infections, including those caused by multi-drug resistant viruses.
The company is led by President and CEO Kenneth I. Moch.